Revenue
2017
2018
2020
2021
2022
2023
2024
2025
Alaunos Therapeutics, Inc. (TCRT)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5,000 | $10,000 | $5,000 | $2.9M | $398,000 | $0 | — | $146,000 | $6.4M | $6.9M | — | — | — | $800,000 | $667,000 | — | — | — | — | — | — | — |
| Research & development | $1.4M | $362,000 | $16.3M | $25.0M | $49.6M | $52.7M | $38.3M | $34.1M | $45.1M | $157.8M | $106.8M | $32.7M | $42.9M | $83.4M | $57.1M | $12.9M | $4.6M | — | — | — | — | — |
| Operating expenses | $4.2M | $4.8M | $34.3M | $38.0M | $77.9M | $80.4M | $57.9M | $54.1M | $59.9M | $172.2M | $124.4M | $44.9M | $58.5M | $103.0M | $72.1M | $24.5M | $12.1M | — | — | — | — | — |
| Operating income | −$4.2M | −$4.8M | −$34.3M | −$35.1M | −$77.5M | −$80.4M | −$57.9M | −$53.9M | −$53.5M | −$165.3M | −$120.1M | −$43.5M | −$57.7M | −$102.2M | −$71.4M | −$24.5M | −$12.1M | — | — | — | — | — |
| EBITDAderived | — | — | — | — | — | — | — | — | — | −$165.0M | −$119.7M | −$43.0M | −$57.0M | −$101.5M | −$71.1M | −$24.4M | −$11.8M | — | — | — | — | — |
| Net income | −$4.2M | −$4.7M | −$4.7M | −$37.7M | −$78.8M | −$80.0M | −$117.8M | −$53.1M | −$54.3M | −$165.3M | −$120.1M | −$31.8M | −$57.1M | −$96.1M | −$63.8M | −$32.7M | −$7.6M | −$25.2M | −$26.6M | −$17.9M | −$9.5M | −$5.7M |
| Basic EPSper diluted share | -$2.20 | -$2.92 | -$21.97 | -$2.61 | -$0.37 | -$0.38 | -$0.70 | $0.96 | -$0.53 | -$1.32 | -$0.96 | -$0.31 | -$0.66 | -$1.22 | -$0.97 | -$0.71 | -$0.33 | — | — | — | — | — |
| Diluted EPSper diluted share | -$2.20 | -$2.92 | -$21.97 | -$2.61 | -$0.37 | -$0.38 | -$0.70 | $0.96 | -$0.53 | -$1.32 | -$0.96 | -$0.31 | -$0.66 | -$1.22 | -$0.97 | -$0.71 | -$0.33 | — | — | — | — | — |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 24, 2025Form 4 | Vieser JaimeDirector | BuySeries A-2 Convertible Preferred Stock · derivative | 250 | $4.49 | $1.1K | 250 |
| Jun 24, 2025Form 4 | Postma Robert WDirector | BuySeries A-2 Convertible Preferred Stock · derivative · indirect | 600 | $4.49 | $2.7K | 600 |
| Apr 11, 2025Form 4 | Postma Robert WDirector | BuySeries A-1 Convertible Preferred Stock · derivative · indirect | 500 | $2.76 | $1.4K | 500 |
| Apr 11, 2025Form 4 | Postma Robert WDirector | BuySeries A-1 Convertible Preferred Stock · derivative · indirect | 500 | $2.76 | $1.4K | 500 |
| Dec 31, 2024Form 4 | Vieser JaimeDirector | SellCommon Stock | 818 | $2.00 | $1.6K | 25.9K |